Two European partners will soon be vying for dominance in a new battleground: vaccines to protect travelers against a painful ...

A one-fifth dose of Bavarian Nordic’s mpox vaccine Jynneos can elicit a similar antibody response as its standard-dose regimen, according to findings presented Saturday at the European Society of ...

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS ...

Bavarian Nordic will submit additional data over the coming months, aiming to complete the BLA submission before the end of the first half of 2024 to support a potential FDA approval of the vaccine in ...

An official statement from the department says the city has only received a limited supply of the FDA-approved Jynneos monkeypox vaccine, produced by the Danish biotechnology firm Bavarian Nordic ...

COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued at EUR 65 million to supply its MVA-BN ® smallpox vaccine to the strategic ...

COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a ...

To confirm the efficacy of the monkeypox vaccine, Bavarian Nordic will collect data from ... company would be able to absorb the increasing demand despite having only a single production facility.

Ritchie Torres filed legislation this week aimed at improving the HHS' response to mpox and other health emergencies.

should routinely get Bavarian Nordic's JYNNEOS vaccine. The recommendation, however, has not yet been approved by CDC ...

In February 2024, the Committee for Medicinal Products for Human Use (CHMP) under EMA granted accelerated assessment for the MAA for the CHIKV VLP vaccine candidate, which Bavarian Nordic plans to ...

COPENHAGEN, Denmark, April 29, 2024 - Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued at EUR 65 million to supply its MVA-BN ® smallpox vaccine to the strategic ...